AYANA PHARMA LTD
GenericsAYANA PHARMA LTD is a generic drug manufacturer focused on Oncology.
AYANA PHARMA LTD's Key Drugs
AYANA PHARMA LTD's core commercial portfolio centers on DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), spanning Oncology — its most strategically important drugs approved in the last 15 years.
AYANA PHARMA LTD's Recent FDA Approvals
New NDA/BLA approvals for AYANA PHARMA LTD over the last two years — novel drugs only, excluding generics and label supplements.
AYANA PHARMA LTD's Therapeutic Areas
AYANA PHARMA LTD's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AYANA PHARMA LTD's Top Competitors
AYANA PHARMA LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AYANA PHARMA LTD Pipeline Snapshot
AYANA PHARMA LTD has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2021-10-12
- Latest
- 2021-10-12
- Applications
- 1